BALAXI Stock View

Balaxi Pharmaceuticals Ltd

₹ 447.1

Market Cap ₹( Cr.)
Proj. P/E (x)
Proj. P/BV (x)
Proj. ROE (%)
Proj EV / EBITDA (x)
Proj. Revenue ( Cr.)

Stock View

Last Updated On.

The average score for Balaxi Pharmaceuticals Ltd stands at 6 against 8, three months back.

Balaxi Pharmaceuticals Limited is an India-based intellectual property research (IPR) pharmaceutical company. The Company is focusing on frontier markets, with a growing portfolio of drugs across multiple therapeutic segments. It has a portfolio across multiple therapeutic segments, stock & sell models, and supplying branded and generic medicines. The Company is offerings more than 300 products across multiple therapeutic areas, including Anti-biotic, Analgesic, Medical Device, Vitamins, Anti-Malaria, Erectile Dysfunction, Hypertension, Anti-Asthma, Steroid, Anti-Helminthic, Anti-Ulcer, Hygiene, Anticholinergic, Dietary Supplement, Diuretic, Hormone, Anti-Emetic, Bronchodilator, Local Anesthetic, Anemia, Anti-Diarrhoea, Antihistamine, Hypotension, Antacid, Anti-Tuberculosis, Insect Repellents and Laxative. Its consumer products include Nice 45 G, Guloso 45 G, Snax! 42 G, Doce E Sal 42 G, Yumm 75 G and Boadent.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required